Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0EIVTA
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
EP4461318A2 anti-PSMA ADC15
|
|||||
| Synonyms |
anti-PSMA ADC15
Click to Show/Hide
|
|||||
| Organization |
Ambrx,Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1.8-2
|
|||||
| Antibody Name |
Chimeric Anti-PSMA Antibody
|
Antibody Info | ||||
| Antigen Name |
Glutamate carboxypeptidase 2 (FOLH1)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Short Cleavable (Valine-Citruline-Acetyl)
|
Linker Info | ||||
| Conjugate Type |
Lysine amide coupling
|
|||||
| Combination Type |
Short Cleavable (Valine-Citruline-Acetyl)-MMAE
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.425 nM | High FOLH1 expression (FOLH1 +++) | ||
| Method Description |
In Vitro Potency Studies - In vitro potency of anti-PSMA ADCs is determined using a metastatic castration-resistant prostate cancer (mCRPC) representative cell-line, C4-2. The cell culture is incubated with antibody drug conjugates for 96 hours at 37C. Cell viability is analyzed using Cell Titer GlO (Promega, USA). Anti-proliferative activity is represented by potency, ICso, the concentration at which 50% of the maximum activity is achieved and cell killing, and Emax, the maximum level of growth inhibition. Table 5 summarizes the cell killing and in vitro potency of the anti-PSMA ADCs.
Click to Show/Hide
|
||||
| In Vitro Model | Prostate carcinoma | C4-2 cells | CVCL_4782 | ||